Delving into the Latest Updates on Timolol with Synapse

The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and requiring cataract surgery.
The main questions it aims to answer are how safe are three different doses of the investigational drug is and how the body tolerates it.
The study will also check:
* how safely the implant is placed in and removed from the eye and how the body responds to the procedure,
* if and the amount of Timolol released in the bloodstream,
* if there is any positive effect on the pressure inside the eye.

Start Date12 Jun 2025

Sponsor / Collaborator

EyeD Pharma SA

NCT06643416

/ RecruitingPhase 3IIT

Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial

To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.

Start Date09 Oct 2024

Sponsor / Collaborator

Queen Mary Hospital

NCT06120140

/ RecruitingPhase 2

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes an Expansion cohort to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

Start Date16 Feb 2024

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Timolol

Login to view more data

100 Translational Medicine associated with Timolol

Login to view more data

100 Patents (Medical) associated with Timolol

Login to view more data

5,361

Literatures (Medical) associated with Timolol

01 Oct 2025·Photodiagnosis and Photodynamic Therapy

Effects of topical coenzyme Q10 in conjunction with vitamin e on the pattern visual evoked potential, visual field, retinal ganglion cell layer and retinal nerve fibre layer thickness in patients with primary open-angle glaucoma

Article

Author: Dogan, Mahmut ; Mirza, Galip Ertugrul

PURPOSE:

To evaluate the effects of coenzyme Q10+vitamin E on the pattern visual evoked potential (VEP), visual field, retinal ganglion cell layer and RNFLthickness in patients with primary open-angle glaucoma (POAG).

METHODS:

Ninety-six eyes from forty-eight POAG patients were enrolled. Forty-eight eyes were chosen for the study group, and fellow forty-eight eyes were chosen for the control group. At baseline, 6th month, and 12th month, the VEP, visual field parameters, and optical coherence tomography (OCT) (i.e.RNFL) were recorded for the 48 POAG eyes that underwent treatment with coenzyme Q10+vitamin E (Coqun®) in addition timolol+dorzolamide in study group and for the 48 POAG eyes that were only treated with timolol+dorzolamide in control group.

RESULTS:

After 12 months, ganglion cell layer of both groups were decreased when compared to baseline (p < 0.05). Although the decrease in the ganglion cell layer in the control group was greater. After 12 months, in control group patients VEP P100 implicit times were increased, whereas P100 amplitudes were decreased (P < 0.05) .In study group patients, VEP P100 implicit times were decreased, whereas P100 amplitudes were increased (P < 0.05) when compared to baseline. At the end of 12 months in the study group, there was no significant change in the 32 patients ( %67), and the current visual field was preserved. (p > 0.05).In the control group at the end of the12 month, 24 ( %50)patients had an increase in MD (p < 0.05). In both groups, the RNFL thickness at 12 months showed a significant decrease (p˂ 0.05) compared to baseline.

CONCLUSION:

Currently, neuroprotective drug studies in glaucoma are increasing daily.These results suggest that Coqun® administration in POAG had a beneficial effect on the inner retinal layer with consequent enhancement of the visual cortical responses (VEP improvement),visual field (decreased MD) and protect RNFL thickness.

25 Sep 2025·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Genetics and general dermatology

Article

Author: Abbasi, Mohammed ; Dubash, Faisal ; Pudasaini, Prajwal

A 70-year-old man from rural Nepal presented with a history of widespread, multiple small red lacy lines over his face, trunk, upper limbs and soft palate, for the past 55 years. He had recurrent episodes of nasal epistaxis and gingival bleeding, with repeated nasal packing. There was no history of gastrointestinal or central nervous system bleeding. His father had similar lesions over the skin without any bleeding diathesis. On examination, he had multiple cutaneous nonblanching telangiectasias with soft palate involvement. He was treated with intranasal topical timolol and septodermoplasty by the ear, nose and throat team.

24 Sep 2025·Retinal cases & brief reports

Peripapillary retinoschisis associated with open angle glaucoma responding to dorzolamide

Article

Author: Golebka, Jedrzej ; Flynn, Erin ; Chang, Stanley ; Moussa, Omar

Purpose::

Presenting a case of peripapillary retinoschisis in a patient with glaucomatous optic neuropathy that resolved after changing therapy from topical bimatoprost to timolol/dorzolamide.

Methods::

A 70-year-old female who presented for a second opinion for peripapillary retinoschisis in the left eye.

Results::

The patient’s visual acuity was 20/25 and 20/30 in the right and left eyes, respectively. Dilated fundoscopy revealed posterior vitreous detachment (PVD) of the left eye, temporal cupping with a superotemporal notch of the left optic nerve, and bilateral macular drusen and pigmentary changes of the retinal pigment epithelium (RPE). Optical coherence tomography of the macula of the left eye showed a PVD, drusen, and peripapillary retinoschisis extending to and involving the fovea. Topical prostaglandin analogue eye drop was discontinued and replaced by dorzolamide/timolol. The peripapillary retinoschisis resolved after medication change over the following 48 months and has not recurred.

Conclusion::

We present a case of peripapillary retinoschisis in a phakic patient that developed during treatment with a topical prostaglandin analogue. The schisis resolved after switching the prostaglandin analogue to a topical carbonic anhydrase inhibitor. We suggest that the prostaglandin may have had a role in initiating peripapillary retinoschisis associated with glaucomatous optic neuropathy and that carbonic anhydrase inhibitors are a potential treatment for this condition.

21

News (Medical) associated with Timolol

07 Apr 2025

·www.pharmaceutical-technology.com

China’s NMPA authorises Santen’s glaucoma treatment application

The eyedrop is an option for those who are benefitting from preservative-free eye drops. Credit: Andrey Sayfutdinov/Shutterstock. China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen Pharmaceutical’s Tapcom to treat individuals with open-angle glaucoma or ocular hypertension. This fixed-combination eye drop comprising tafluprost 0.0015% and timolol 0.5% is designed to lower intraocular pressure (IOP) for individuals with this condition. Glaucoma damages the optic nerve and results in visual field loss. The eye drop offers a therapeutic alternative for individuals whose topical beta-blockers or prostaglandin derivatives monotherapies have not achieved target IOP. It is also an option for those who are benefitting from preservative-free eye drops in prolonged topical usage of glaucoma medication. Tapcom is the country’s first preservative-free ophthalmic combo formulation to include a first-line prostaglandin derivative. Its two active ingredients, tafluprost and timolol maleate, work through different mechanisms to reduce IOP. Tafluprost acid, the active metabolite of tafluprost, is a prostanoid FP receptor agonist that promotes aqueous humour outflow. A nonselective β-receptor inhibitor, timolol maleate, decreases the production of aqueous humour. Tapcom has gained approval in 40 countries and regions, including Asia and Europe. Santen Pharmaceutical chief medical officer Peter Sallstig stated: “Glaucoma remains the leading cause of irreversible blindness worldwide, deeply impacting the quality of life of many patients. “Therefore, Santen has prioritised glaucoma as a key therapeutic focus, dedicating ourselves to the development of treatments that meet patients’ needs and the delivery of high-quality ophthalmic drugs. The approval of Tapcom in China represents a significant milestone, offering new treatment options for Chinese glaucoma patients and advancing the field of glaucoma care.” In November 2024, the company and Arctic Vision signed a commercial partnership agreement for the ARVN001 suprachoroidal injectable suspension for uveitic macular oedema and other ocular conditions.

Drug Approval

04 Apr 2025

·pharma.economictimes.indiatimes.com

Akums launches ophthalmic drop for Glaucoma and Ocular hypertension

New Delhi: A contract development and manufacturing organisation (CDMO) Akums Drugs & Pharmaceuticals has announced the launch of Ripasudil-Timolol combination therapy for glaucoma treatment . The new combination therapy offers a dual mechanism of action where Ripasudil enhances aqueous humor outflow through the trabecular meshwork and Timolol reduces aqueous humor production, the company said in a release. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments, it added. Commenting over the launch, Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, “This innovation integrates two distinct mechanisms of action to improve glaucoma treatment and our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected.” As per the company, by combining two medications into one product, potentially improved compliance and the single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management —patient adherence. The company release suggest that currently in India around 11.9 million people are affected with glaucoma and the condition stands as the third leading cause of vision impairment in India, after cataract and refractive errors By Online Bureau ,

31 Mar 2025

·www.pharmaindustrial-india.com

Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment

Akums Drugs & Pharmaceuticals Ltd. has announced the launch of a pioneering Ripasudil-Timolol combination therapy for glaucoma treatment. This Drugs Controller General of India (DCGI)-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO to receive approval for this innovative formulation. Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden. The condition remains third among causes of vision impairment in India, after cataract and refractive errors. Also, Ocular hypertension is closely linked to glaucoma, many eye care professionals consider ocular hypertension to be a precursor or warning sign for glaucoma. Ocular hypertension refers to elevated pressure within the eye (intraocular pressure or IOP) that is higher than normal but without detectable damage to the optic nerve or visual field loss that would indicate glaucoma. While not everyone with ocular hypertension develops glaucoma, regular monitoring is crucial. Managing both conditions primarily involves lowering intraocular pressure to prevent further complications. The new combination therapy offers a dual mechanism of action for superior intraocular pressure (IOP) control: Ripasudil enhances aqueous humor outflow through the trabecular meshwork, while Timolol reduces aqueous humor production. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., said, "This innovation integrates two distinct mechanisms of action to improve glaucoma treatment. By enhancing efficacy and ease of use, we aim to offer a more practical and patient-friendly solution. Our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected. With a patient-first approach and a commitment to Make in India, we continue to develop solutions that are of high-quality, and aligned with global standards." The single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management—patient adherence. By combining two medications into one product, patients benefit from enhanced convenience and potentially improved compliance. "With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial," added Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. "This launch marks a significant step in making high-quality and effective treatment more accessible," added Jain. Akums will utilise its manufacturing facilities to ensure consistent supply and the broad availability of this breakthrough therapy. With approximately 11.9 million people affected by glaucoma in India, this innovative combination addresses a critical healthcare need by providing an effective solution that simplifies treatment while potentially improving outcomes.

100 Deals associated with Timolol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08600	Timolol	S01ED01 C07AA06	DB00373

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Thea Pharma, Inc.	31 Mar 1995

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 3	-	Alcon Research Ltd.	01 Dec 2007
Glaucoma	Phase 3	United States	Alcon Research Ltd.	01 Jan 2003
Dry Eye Syndromes	Phase 2	-	Novaliq GmbH	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03282981 (BAART-DFU, CTgov)	Phase 3	Diabetic foot ulcer \| Wounds and Injuries	48	Timolol (Timolol)	rtdbnqxrkj = wlskxdrnyo gvplginwiu (ctvqkqmjjo, huatnftylm - zebagqrdnc) View more	-	25 Apr 2025
				Non biologically active gel (SOC Plus Non Biologically Active Gel)	rtdbnqxrkj = qsisjngxto gvplginwiu (ctvqkqmjjo, vmikyuamyk - zfgjcjesrz) View more
NCT03836664 (CTgov)	Phase 2	Migraine Disorders	25	Timolol (All Participants Post Timolol)	jgkevjkjzu(irkzhdpafg) = maxqmglcwd ngjwuoyhcd (kbsfxjbmeu, dzfubejmlu - ameljmkrih) View more	-	02 Jul 2019
				placebo+Timolol (All Participants Post Placebo)	jgkevjkjzu(irkzhdpafg) = kuzfjycgne ngjwuoyhcd (kbsfxjbmeu, lyvcfpvzrp - fgrkfmmxdy) View more
NCT01677507 (ARVO2019)	Phase 4	-	121	Timolol 0.5%	itzbwbywim(afuwrnucbo) = dcokxirkbx tfdvkwsxkr (uzjjxxorkb, 7.9)	Positive	01 Jul 2019
				Latanoprost 0.005%	itzbwbywim(afuwrnucbo) = kehuxxttlb tfdvkwsxkr (uzjjxxorkb, 7.9)
NCT02630719 (CTgov)	Not Applicable	Migraine Disorders	10	Timolol eye drops (Timolol Eye Drops)	sdhuwdpyxi(gjtvewgeiz) = elixlokhom tjvwtlgrev (ogoazsowms, 31) View more	-	15 May 2019
				Artificial tears (Artificial Tears)	sdhuwdpyxi(gjtvewgeiz) = duylacngpv tjvwtlgrev (ogoazsowms, 30) View more
NCT00572936 (CTgov)	Phase 2	Glaucoma	30	Latanoprost (Latanoprost)	uhzhjywcvg(cdwvwqsbyn) = hqqwvbotmb rdmscfjswq (gdxqlswsts, 3.7) View more	-	14 Feb 2018
				Timolol (Timolol)	uhzhjywcvg(cdwvwqsbyn) = ljrzmkatcd rdmscfjswq (gdxqlswsts, 2.3) View more
NCT02097719 (CTgov)	Phase 4	Glaucoma	100	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	zeaetbkows(orrujdbdmb) = nvnlwrbgio fxrznmjsln (kgcfjeujha, 0.50) View more	-	14 Jan 2016
				timolol 0.5%+travoprost 0.004% (Travoprost 0.004% and Timolol 0.5%)	zeaetbkows(orrujdbdmb) = ycspumdldy fxrznmjsln (kgcfjeujha, 0.48) View more
NCT01881126 (CTgov)	Phase 4	Glaucoma	93	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	sondrekqxy(iuaqocbyvk) = ulvfzgsgxa qztajqzidd (ehfveikdcv, 0.46) View more	-	30 Nov 2015
				timolol 0.5%+travatan 0.004% (Travatan 0.004% and Timolol 0.5%)	sondrekqxy(iuaqocbyvk) = hsfqidhthj qztajqzidd (ehfveikdcv, 0.43) View more
NCT01506635 (Pubmed \| Am J Ophthalmol)	Not Applicable	-	124	Timolol 0.5% eye drops	zjsutdxfyx(ejmciqylaf) = fyisanxoqc vyfohwwuss (ktxghpekqc )	Positive	01 Nov 2012
				Artificial tears	zjsutdxfyx(ejmciqylaf) = ynvkmmvtpz vyfohwwuss (ktxghpekqc )
NCT00508469 (CTgov)	Phase 4	Glaucoma, Open-Angle	102	Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination)	tijivzguhf = ujvkexpzmy xcvhgokois (zwaigkkrml, hlibinuxhi - mobijanbky) View more	-	12 Jul 2012
				Travalert Dosing Aid+Timolol+Travoprost (Travalert With Travoprost and Timolol)	tijivzguhf = rcwhdlfhru xcvhgokois (zwaigkkrml, mgtnbteonp - dgdnbntvcp) View more
NCT00572936 (ARVO2010)	Phase 2	Glaucoma	-	Timolol 0.5%	teoyipspwc(foofeisxdn) = qgsnvcrrgu nocirhvlyy (dkzdjcixan ) View more	Positive	01 Apr 2010